In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $53.29 in the prior trading day, Moderna Inc (NASDAQ: MRNA) closed at $51.81, down -2.78%. In other words, the price has decreased by -$2.78 from its previous closing price. On the day, 10.36 million shares were traded. MRNA stock price reached its highest trading level at $52.855 during the session, while it also had its lowest trading level at $49.6.
Ratios:
Our goal is to gain a better understanding of MRNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 4.09. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bernstein on October 17, 2024, initiated with a Mkt Perform rating and assigned the stock a target price of $55.
JP Morgan Downgraded its Neutral to Underweight on September 13, 2024, whereas the target price for the stock was revised from $88 to $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 07 ’24 when Mock James M sold 715 shares for $60.12 per share. The transaction valued at 42,986 led to the insider holds 9,505 shares of the business.
Klinger Shannon Thyme sold 551 shares of MRNA for $40,539 on Sep 09 ’24. The Chief Legal Officer now owns 18,154 shares after completing the transaction at $73.57 per share. On Sep 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Officer of the company, bought 551 shares for $73.57 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 19915556864 and an Enterprise Value of 12696558592. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.95 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 2.514 whereas that against EBITDA is -3.091.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $52.08. The 50-Day Moving Average of the stock is -17.79%, while the 200-Day Moving Average is calculated to be -48.00%.
Shares Statistics:
The stock has traded on average 4.81M shares per day over the past 3-months and 4574700 shares per day over the last 10 days, according to various share statistics. A total of 382.00M shares are outstanding, with a floating share count of 342.76M. Insiders hold about 10.83% of the company’s shares, while institutions hold 67.82% stake in the company. Shares short for MRNA as of 1728950400 were 33260603 with a Short Ratio of 6.92, compared to 1726185600 on 27613114. Therefore, it implies a Short% of Shares Outstanding of 33260603 and a Short% of Float of 11.3800004.
